Figure 3. DKK1-targeted therapies in MBD.
DKK1 secreted by myeloma cells provides us a potentially therapeutic means of intervention in drug discovery. DKK1 targeted therapies, including DKK1 neutralizing antibodies, proteasome inhibitor, vaccine and regulatory factor (e.g. ET-1), have been carried out and all of them have shown many curative clinical benefits on MBD.